Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoxantrone SCHEMBL29462659 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11305688 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL29366412 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL10522176 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL1256885 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11039686 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL66384 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL3928 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL2342900 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11278695 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| WO-2005079419-A2 | METHODS OF TREATING IMMUNOPATHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-01 | — | — | WO | claimed |
| EP-3676363-A1 | PERFUSION APPARATUS FOR USE IN BIOREACTOR SYSTEMS | Lonza Ltd (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3525904-A1 | FILTER ASSEMBLY WITH FILTER LOCK DESIGN | Lonza Limited (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019067966-A1 | PERFUSION APPARATUS FOR USE IN BIOREACTOR SYSTEMS | LONZA LTD. (CH) | 2019-04-04 | — | — | WO | disclosed |
| EP-3423588-A1 | IMPROVED FERMENTATION PROCESS | Lonza Ltd (CH) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018150271-A1 | MAMMALIAN CELLS FOR PRODUCING ADENO-ASSOCIATED VIRUSES | LONZA LTD. (CH) | 2018-08-23 | — | — | WO | disclosed |
| WO-2018150269-A1 | MULTI-SITE SPECIFIC INTEGRATION CELLS FOR DIFFICULT TO EXPRESS PROTEINS | LONZA LTD. (CH) | 2018-08-23 | — | — | WO | disclosed |
| CN-106551934-A | A kind of pharmaceutical composition and its application | 康朴生物医药技术（上海）有限公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-102985089-B | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | ESTEVE LABOR DR | 2015-07-15 | — | — | CN | disclosed |
| EP-2441465-B1 | Compositions and methods for healthy pregnancy | NORA THERAPEUTICS INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20080213211-A1 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY | NORA THERAPEUTICS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213301-A1 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY | NORA, LLC (US) | 2008-09-04 | — | — | US | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20070071716-A1 | Compositions and methods for healthy pregnancy | NORA LLC (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060258656-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| EP-1682074-A2 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY | Nora, LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005039505-A2 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY | NORA, LLC (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258656-A1 | Compositions and methods for treating cancer | HIF1A, HIF1AN, EGLN3 | TOP2A 189/4885MEN1 3536/4885KMT2A 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.